



# Bactiguard announces updated strategic and financial targets

**Bactiguard Holding AB (publ.) today announces its updated strategic and financial targets following a review announced in connection with the 2024 Q3 report. The updated targets reflect a sharpened strategic focus on the license business and EBITDA profitability, a transformation delivered in 2024. The updated strategic and financial targets will be presented at an audiocast tomorrow 6 March at 10:00 CET.**

Bactiguard has conducted a comprehensive analysis of the market potential and partnership opportunities for its infection prevention technology. This includes an in-depth evaluation of key strategic therapeutic areas, targeted application areas, associated infection rates, regulatory approval timelines, partner timelines and commercial scale-up potential.

As a result of the review, Bactiguard will focus on five strategic therapeutic areas: Orthopedics, Vascular Access, Cardiology, Neurology, and Urology. The updated strategic and financial targets are the following:

**Partnership development:** have at least ten application areas in either exclusivity partnerships or license partnerships by year-end 2030

**Revenues:** deliver revenues of at least SEK 600 million by year-end 2030

**EBITDA:** deliver an EBITDA of at least SEK 200 million by year-end 2030

Bactiguard will maintain its focus on EBITDA profitability including a disciplined approach to costs. The financial targets above include both the license business and the wound management product portfolio. For the wound management portfolio, we expect continued profitable double-digit growth.

Christine Lind, CEO of Bactiguard comments, "One year into our license-focused strategy, we are refining our targeted therapeutic areas and associated application areas to focus where our technology holds the greatest realizable potential. This is reflected in our updated strategic partnership and financial targets. With our strengthened capabilities and continued investments in R&D, regulatory expertise, and new business development, we are well-positioned to capitalize on the opportunities for our infection prevention technology. While we have set targets for 2030, the potential for our technology platform over the longer-term is significant. The operational leverage and scale inherent in our business model is expected to be even more meaningful in the years beyond 2030, through partnerships announced over the coming years."

The above strategic and financial targets replace the previous targets announced in October 2023. The previous targets were EBITDA of SEK 500 million by year-end 2028, net sales in excess of SEK 1 billion by year-end 2028, and at least 10 application areas in license partnerships with products in the market by year-end 2028.

The updated financial targets should not be perceived as a forecast but rather reflect what the Bactiguard Holding AB Board of Directors and Executive Management team consider to be reasonable mid-term expectations of Bactiguard.

Bactiguard will host an audiocast in English for investors, analysts, and media tomorrow 6 March at 10:00 CET. CEO Christine Lind and CFO Patrick Bach will present the updated therapeutic areas and targets, and answer questions. The presentation will be available at [ir.bactiguard.com](http://ir.bactiguard.com) after the audiocast.

To participate in the audiocast (or participate in the conference call only), please use this link:  
<http://ir.bactiguard.com/updated-strategic-and-financial-targets>

*This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below, 2025-03-05 at 18:15 CET.*

**For further information, please contact:**

Patrick Bach, CFO +46 761 295 911

Nina Nornholm, Head of Communications & Investor Relations +46 708 550 356

## About Bactiguard

Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The company's unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard's infection prevention technology and solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine.

Bactiguard operates through license partnerships with leading global MedTech companies that apply the technology to their medical devices and sell them under their own brand or co-branded with Bactiguard. The company also has a portfolio of wound management products. Bactiguard is headquartered in Stockholm and listed on Nasdaq Stockholm.

*Read more about Bactiguard: [www.bactiguard.com](http://www.bactiguard.com)*

*Follow Bactiguard on [LinkedIn](#)*